EP-1355: Combined and modulated adjuvant therapy in prostate carcinoma: a phase I-II trial  by Nuzzo, M. et al.
ESTRO 35 2016                                                                                                                                                    S633 
________________________________________________________________________________ 
compare available evidence of carbon ion therapy prostatic 
cancer by meta analysis. 
 
Material and Methods: PubMed,Embase,The Cochrane 
Library,Web of Science,the Chinese Biomedical Literature 
Database were systemically searched from 1980 to May 2015 
by heavy ion,carbon ion,carbon and 12C6+,to collect clinical 
study of carbon-ion radiotherapy for prostatic cancer.Two 
reviews independently screened citation extracted basic 
information of local control rate,overall survival rate and 
phase of clinical study,the related data were analyzed by 
Stata 12.0. 
 
Results: Three phase II clinical trials,four phase I/II clinical 
trials and one retrospective study were included,which 
included 1307 patients.the meta analysis showed 3-,4-,5-,and 
8-year overall survival rates were 
0.934(95%CI:0.901,0.968),0.909(95%CI:0.866,0.951),0.872(95
%CI:0.844,0.899) and 0.839(95%CI:0.793,0.884) and the 4-, 5-
year local control rate were 0.989(95%CI:0.973,1.004) and 
0.99(95%CI:0.969,1.01), respectively(Figure 1). 
 
 
Conclusion: Carbon ion therapy is suitable and tolerable for 
the treatment of prostate cancer, in the future,more 
evidence is required before carbon ion therapy can become 
internationally the standard treatment for prostate cancer 
patients. 
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Purpose or Objective: EORTC trial 22911 showed 75% 5-year 
biochemical disease-free survival (BDFS) in patients with 
prostate carcinoma (PCa) treated with radical prostatectomy 
(RP) followed by postoperative radiotherapy (RT). Aim of this 
study was to improve this outcomes by using a combined-
intensified-modulated-adjuvant (CIMA) treatment, based on 
RT and adjuvant hormone therapy (AHT). 
 
Material and Methods: The study hypothesis was that CIMA 
treatment may improve 5-year BDFS from 75% to 90%. The 
study was planned based on Simon’s phase II design. We 
needed to study 100 experimental subjects to be able to 
reject the null hypothesis that the success rates for standard 
and experimental treatments are equal with probability 
(power) 0.8. The Type I error probability associated with this 
test of this null hypothesis is 0.05. We used an uncorrected 
chi-squared statistic to evaluate this null hypothesis. Some 
over-recruitment was planned to allow for a continuous drop-
out process of up to 20% during the follow-up period. 
Enrolled patients were < 80 years old, with histological 
diagnosis of PCa, without known metastases, stage pT2-4 N0-
1, not previously treated and with ECOG performance status 
of 0-2. All patients had at least one of these pathologic 
features: capsular perforation, positive surgical margins, 
seminal vesicle invasion. Standard dose to the tumor bed was 
64.8 Gy. According to the pathological stage patients 
received a higher dose (70.2 Gy; 85.4%) and/or prophylactic 
irradiation of pelvic lymph nodes (57.7%) and/or adjuvant 
hormonal therapy (69.1%). 
 
Results: One-hundred-twenty-three patients were enrolled in 
the study and completed the planned CIMA treatment. 
Median preoperative and postoperative PSA were 8.8 and 
0.06 ng/dL, respectively. Proportion of patients with 
pathologically involved nodes and positive resection margin 
was 14.6 % and 58.5%, respectively. Median follow-up was 67 
months (interquartile range: 48.0-98.0 months). Actuarial 5-
year BDSF was 92.9%. Actuarial 5-year local control and 
metastasis-free survival were 99% and 96%, respectively. 
Actuarial 5-year overall survival was 95%. 
 
Conclusion: CIMA therapy, compared to studies based on 
standard adjuvant radiotherapy, resulted in an improved 5-
year BDFS, although patients with nodal metastatic disease 
and detectable postoperative PSA were enrolled in the study. 
A prolonged follow-up will be needed to confirm this 
improvement even in terms of disease-free survival and 
overall survival. 
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Purpose or Objective: Despite 3 large randomized studies on 
adjuvant radiotherapy (RT) proving a significantly improved 
biochemical recurrence free survival in patients (pts) with 
advanced prostate cancer (PCA), there is still an dispute 
regarding the need for adjuvant RT in those pts. The risk of 
recurrence in these advanced stages may reach 30% to 60%. 
Nevertheless many of those pts are not referred to adjuvant 
RT. We therefore performed a retrospective analysis of 94 
pts with pT3a pN0/cN0 R1-resected PCA in order to 
investigate the natural history of the disease and the benefit 
of adjuvant or salvage RT. 
 
Material and Methods: We included 94 pts with pT3a 
pN0/cN0 R1-resected PCA that had undergone prostatectomy 
no later than 2009. In 91 pts lymphadenectomy was 
performed with an average of 10 removed lymph nodes. 
Gleason-Score was mainly 7a in 33, 7b in 24 and 8 in 19 pts. 
Statistical analysis was performed using a Cox proportional 
hazard model and Kaplan Meier survival analysis. Median 
follow up was 80 months. 
 
Results: 71 pts had a PSA <0.07ng/ml after surgery. 35 of 
them experienced a biochemical relapse (Group 1). In 30 pts 
this occurred within the first 80 months. 28 of the pts with 
biochemical relapse received early salvage RT. PSA before 
salvage RT was in median 0.24ng/ml and after RT in 23 pts 
<0.07ng/ml. 36 pts were PSA negative after surgery and did 
not have any PSA relapse (Group 2). Nevertheless 14 of these 
pts received an additive RT treatment within the first 15 
months after surgery. At the last date of contact all 36 pts 
were still PSA negative. 23 pts were PSA positive after 
surgery (Group 3). 18 pts received an early salvage RT with a 
PSA in median of 0.4ng/ml (0.12-4.58). After RT PSA was 
0.28ng/ml (0.0-4.58). 5 pts in Group 1, 1 patient in Group 2 
and 9 pts in Group 3 received androgen deprivation therapy 
(ADT) after radiotherapy until the last date of contact. 
